The Center for the Neurobiology of Addiction Treatment (CNAT) is a new version of a PSO Center at Wake Forest University Health Sciences that has been continuously funded by NIDA since 1991.
The Specific Aims are: 1. to provide a novel mechanism of interaction between NIDA Investigators at Wake Forest University to examine neurobiological mechanisms of cocaine pharmacotherapies, using tightly interacting projects to ensure an effective collaborative structure;2. to provide a formal structure of collaborative interactions between our Center and our clinical partners at two NIDA-funded clinical centers, thus providing a novel translational component to our research;3. to provide a focus for the training of students and postdoctoral fellows in contemporary methods for investigating the neurobiological basis of drug abuse;4. to serve as an information source to both the lay and scientific community on issues related to the neurobiological aspects of drug abuse. The scientific theme of the Center is focused on examining the neurobiological mechanisms of action of drugs that are currently used, or proposed for use in the clinic for treatment of cocaine addiction;these studies will begin with topiramate, and proceed with other potential treatment agents including modafinil, D3 dopamine antagonists, orexin antagonists, and others. The Center will accomplish these goals through the activities of two cores and three major projects. The projects are designed to be highly interactive, with each project's activities dependent on results obtained from the other two projects. Project 1 will examine effects of drug treatment on various behavioral models in both rats and monkeys;Project 2 will explore how these drug treatment paradigms affect functional consequences in brain through neuro-imaging and voltammetry;and Project 3 will explore how these drug treatments affect gene and protein expression, receptor function and signal transduction systems in brain tissue obtained from the other Projects. A unique aspect of the Center is the close interaction with two clinical Centers (at the University of Pennsylvania and the University of Virginia) to provide translational capabilities. The Administrative Core will coordinate Center activities, conduct a pilot studies program, and provide for annual meetings with clinical Centers. The Tissue Core will provide uniform sets of brain tissue samples to the projects for individual studies. These projects utilize several animal models and technologies uniquely developed by the Center investigators over the previous years of its funding history.

Public Health Relevance

Drug addiction is a debilitating brain disease and it is crucial to develop novel medications as therapeutic agents to treat addictions to drugs like cocaine. The goal of the Center for the Neurobiology of Addiction Treatment is to study the neurobiological mechanisms of these drugs in models including cell culture, rodents and non-human primates, so that better strategies of drug treatment can be developed.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA006634-22
Application #
8471077
Study Section
Special Emphasis Panel (ZDA1-EXL-T (11))
Program Officer
Volman, Susan
Project Start
1991-09-30
Project End
2014-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
22
Fiscal Year
2013
Total Cost
$1,461,781
Indirect Cost
$559,740
Name
Wake Forest University Health Sciences
Department
Physiology
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Siciliano, Cody A; Saha, Kaustuv; Calipari, Erin S et al. (2018) Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation. J Neurosci 38:484-497
Ilyasov, Alexander A; Milligan, Carolanne E; Pharr, Emily P et al. (2018) The Endocannabinoid System and Oligodendrocytes in Health and Disease. Front Neurosci 12:733
Ding, Huiping; Kiguchi, Norikazu; Yasuda, Dennis et al. (2018) A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Sci Transl Med 10:
Chen, R; McIntosh, S; Hemby, S E et al. (2018) High and low doses of cocaine intake are differentially regulated by dopamine D2 receptors in the ventral tegmental area and the nucleus accumbens. Neurosci Lett 671:133-139
John, William S; Martin, Thomas J; Solingapuram Sai, Kiran Kumar et al. (2018) Chronic ?9-THC in Rhesus Monkeys: Effects on Cognitive Performance and Dopamine D2/D3 Receptor Availability. J Pharmacol Exp Ther 364:300-310
Blume, Lawrence C; Patten, Theresa; Eldeeb, Khalil et al. (2017) Cannabinoid Receptor Interacting Protein 1a Competition with ?-Arrestin for CB1 Receptor Binding Sites. Mol Pharmacol 91:75-86
Wesley, Michael J; Lile, Joshua A; Fillmore, Mark T et al. (2017) Neurophysiological capacity in a working memory task differentiates dependent from nondependent heavy drinkers and controls. Drug Alcohol Depend 175:24-35
John, William S; Martin, Thomas J; Nader, Michael A (2017) Behavioral Determinants of Cannabinoid Self-Administration in Old World Monkeys. Neuropsychopharmacology 42:1522-1530
Melchior, James R; Jones, Sara R (2017) Chronic ethanol exposure increases inhibition of optically targeted phasic dopamine release in the nucleus accumbens core and medial shell ex vivo. Mol Cell Neurosci 85:93-104
Namjoshi, Sanjeev V; Raab-Graham, Kimberly F (2017) Screening the Molecular Framework Underlying Local Dendritic mRNA Translation. Front Mol Neurosci 10:45

Showing the most recent 10 out of 310 publications